Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MH-712
- Development stage
- Preclinical
- Lead developer
- Meter Health
01
Overview
MH-712 is an investigational drug candidate being developed by Meter Health for the treatment of oncology-incident clinically significant hiccups. Hiccups in cancer patients are often persistent or intractable, frequently triggered by chemotherapy (especially cisplatin and dexamethasone) or the underlying malignancy itself, significantly impacting quality of life. As of early 2024, MH-712 is in the IND-enabling phase of development. While the specific mechanism of action and modality have not been publicly disclosed by Meter Health, the asset is part of their pipeline targeting supportive care in oncology.
Beyond the preview
Go deeper on MH-712.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MH-712.